As expected, SB939- or 1179.4b-treated mice showed a strong increase in acetylation of histone H3 in primary tumours compared to tumours from control mice, confirming that both SB939 and 1179.4b effectively blocked HDAC activity in vivo and caused reduced primary tumour growth. This evidence concerns the gene HDAC9 and neoplasm.